Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy
- PMID: 25313004
- PMCID: PMC4397150
- DOI: 10.2174/1570161112666141014144829
Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy
Abstract
Vascular diseases are usually caused by multifactorial pathogeneses involving genetic and environmental factors. Our current understanding of vascular disease is, however, based on the focused genotype/phenotype studies driven by the "one-gene/one-phenotype" hypothesis. Drugs with "pure target" at individual molecules involved in the pathophysiological pathways are the mainstream of current clinical treatments and the basis of combination therapy of vascular diseases. Recently, the combination of genomics, proteomics, and metabolomics has unraveled the etiology and pathophysiology of vascular disease in a big-data fashion and also revealed unmatched relationships between the omic variability and the much narrower definition of various clinical phenotypes of vascular disease in individual patients. Here, we introduce the phenomics strategy that will change the conventional focused phenotype/genotype/genome study to a new systematic phenome/genome/proteome approach to the understanding of pathophysiology and combination therapy of vascular disease. A phenome is the sum total of an organism's phenotypic traits that signify the expression of genome and specific environmental influence. Phenomics is the study of phenome to quantitatively correlate complex traits to variability not only in genome, but also in transcriptome, proteome, metabolome, interactome, and environmental factors by exploring the systems biology that links the genomic and phenomic spaces. The application of phenomics and the phenome-wide associated study (PheWAS) will not only identify a systemically-integrated set of biomarkers for diagnosis and prognosis of vascular disease but also provide novel treatment targets for combination therapy and thus make a revolutionary paradigm shift in the clinical treatment of these devastating diseases.
Conflict of interest statement
The authors confirm that this article content has no conflict of interest.
Figures





Similar articles
-
Editorial: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics.Curr Vasc Pharmacol. 2015;13(4):420-2. doi: 10.2174/157016111304150722171221. Curr Vasc Pharmacol. 2015. PMID: 26239638 Free PMC article. No abstract available.
-
Improved drug therapy: triangulating phenomics with genomics and metabolomics.Hum Genomics. 2014 Sep 1;8(1):16. doi: 10.1186/s40246-014-0016-9. Hum Genomics. 2014. PMID: 25181945 Free PMC article. Review.
-
Phenome-wide association study and precision medicine of cardiovascular diseases in the post-COVID-19 era.Acta Pharmacol Sin. 2023 Dec;44(12):2347-2357. doi: 10.1038/s41401-023-01119-1. Epub 2023 Aug 2. Acta Pharmacol Sin. 2023. PMID: 37532784 Free PMC article. Review.
-
From Genome-Wide Association Study to Phenome-Wide Association Study: New Paradigms in Obesity Research.Prog Mol Biol Transl Sci. 2016;140:185-231. doi: 10.1016/bs.pmbts.2016.02.003. Epub 2016 May 14. Prog Mol Biol Transl Sci. 2016. PMID: 27288830 Review.
-
Exploration of variations in proteome and metabolome for predictive diagnostics and personalized treatment algorithms: Innovative approach and examples for potential clinical application.J Proteomics. 2018 Sep 30;188:30-40. doi: 10.1016/j.jprot.2017.08.020. Epub 2017 Aug 26. J Proteomics. 2018. PMID: 28851587 Review.
Cited by
-
Editorial: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics.Curr Vasc Pharmacol. 2015;13(4):420-2. doi: 10.2174/157016111304150722171221. Curr Vasc Pharmacol. 2015. PMID: 26239638 Free PMC article. No abstract available.
-
Novel Biomarkers and Treatments of Cardiac Diseases.Biomed Res Int. 2016;2016:1315627. doi: 10.1155/2016/1315627. Epub 2016 Feb 17. Biomed Res Int. 2016. PMID: 26989677 Free PMC article. No abstract available.
-
Markers of Endothelial Cells in Normal and Pathological Conditions.Biochem (Mosc) Suppl Ser A Membr Cell Biol. 2020;14(3):167-183. doi: 10.1134/S1990747819030140. Epub 2020 Oct 13. Biochem (Mosc) Suppl Ser A Membr Cell Biol. 2020. PMID: 33072245 Free PMC article.
-
Discovery of Drug-Responsive Phenomic Alteration-Related Driver Genes in the Treatment of Coronary Heart Disease.Pharmgenomics Pers Med. 2023 Mar 15;16:201-217. doi: 10.2147/PGPM.S398522. eCollection 2023. Pharmgenomics Pers Med. 2023. PMID: 36945217 Free PMC article.
-
Markers and Biomarkers of Endothelium: When Something Is Rotten in the State.Oxid Med Cell Longev. 2017;2017:9759735. doi: 10.1155/2017/9759735. Epub 2017 Nov 23. Oxid Med Cell Longev. 2017. PMID: 29333215 Free PMC article. Review.
References
-
- Iacoviello L., Donati M.B. Gene-environment interactions: implications for cardiovascular disease. Cardiologia. 1999;44:227–232. - PubMed
-
- Nordon I., Brar R., Hinchliffe R., Cockerill G., Loftus I., Thompson M. The role of proteomic research in vascular disease. J. Vasc. Surg. 2009;49:1602–1612. - PubMed
-
- Rafter N., Connor J., Hall J., et al. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. N. Z. Med. J. 2005;118:U1676. - PubMed
-
- Weir M.R. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. J. Hum. Hypertens. 2007;21:770–779. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical